Answers are grounded in this paper and cite their sources.
Extract The 2025 European Respiratory Society (ERS) Congress provided a comprehensive overview of contemporary advances in pulmonary vascular diseases, reflecting a shift towards precision medicine across pulmonary hypertension (PH) phenotypes. This summary, written collaboratively by both early career members and experts in pulmonary vascular diseases, emphasises key themes including improved phenotyping beyond haemodynamics, integration of right ventricular (RV) biology into therapeutic decision-making, earlier initiation of disease-modifying strategies, and the development of structured care models to optimise outcomes. This article focuses on pulmonary arterial hypertension (PAH), PH associated with lung diseases, chronic thromboembolic pulmonary hypertension (CTEPH), and acute pulmonary embolism (PE), highlighting both shared and disease-specific insights.
No takes yet. Share an insight, caveat, or question.
Budhram et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: